We collect cookies to enhance your browsing experience Learn more

Breast Cancer Therapeutics Market Size, Share, and Trends 2024 to 2034

The global breast cancer therapeutics market size accounted for USD 33.45 billion in 2025 and is forecasted to hit around USD 62.86 billion by 2034, representing a CAGR of 7.27% from 2025 to 2034. The North America market size was estimated at USD 11.22 billion in 2024 and is expanding at a CAGR of 7.41% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : March 2024
  • Report Code : 3949
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Breast Cancer Therapeutics Market 

5.1. COVID-19 Landscape: Breast Cancer Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Breast Cancer Therapeutics Market, By Therapy

8.1. Breast Cancer Therapeutics Market, by Therapy

8.1.1 Targeted Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Hormonal therapy

8.1.2.1. Market Revenue and Forecast

8.1.3. Chemotherapy

8.1.3.1. Market Revenue and Forecast

8.1.4. Immunotherapy

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Breast Cancer Therapeutics Market, By Cancer Type

9.1. Breast Cancer Therapeutics Market, by Cancer Type

9.1.1. Hormone Receptors

9.1.1.1. Market Revenue and Forecast

9.1.2. HER2+

9.1.2.1. Market Revenue and Forecast

Chapter 10. Global Breast Cancer Therapeutics Market, By Distribution Channel 

10.1. Breast Cancer Therapeutics Market, by Distribution Channel

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Breast Cancer Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Therapy

11.1.2. Market Revenue and Forecast, by Cancer Type

11.1.3. Market Revenue and Forecast, by Distribution Channel

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Therapy

11.1.4.2. Market Revenue and Forecast, by Cancer Type

11.1.4.3. Market Revenue and Forecast, by Distribution Channel

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Therapy

11.1.5.2. Market Revenue and Forecast, by Cancer Type

11.1.5.3. Market Revenue and Forecast, by Distribution Channel

11.2. Europe

11.2.1. Market Revenue and Forecast, by Therapy

11.2.2. Market Revenue and Forecast, by Cancer Type

11.2.3. Market Revenue and Forecast, by Distribution Channel

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Therapy

11.2.4.2. Market Revenue and Forecast, by Cancer Type

11.2.4.3. Market Revenue and Forecast, by Distribution Channel

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Therapy

11.2.5.2. Market Revenue and Forecast, by Cancer Type

11.2.5.3. Market Revenue and Forecast, by Distribution Channel

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Therapy

11.2.6.2. Market Revenue and Forecast, by Cancer Type

11.2.6.3. Market Revenue and Forecast, by Distribution Channel

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Therapy

11.2.7.2. Market Revenue and Forecast, by Cancer Type

11.2.7.3. Market Revenue and Forecast, by Distribution Channel

11.3. APAC

11.3.1. Market Revenue and Forecast, by Therapy

11.3.2. Market Revenue and Forecast, by Cancer Type

11.3.3. Market Revenue and Forecast, by Distribution Channel

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Therapy

11.3.4.2. Market Revenue and Forecast, by Cancer Type

11.3.4.3. Market Revenue and Forecast, by Distribution Channel

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Therapy

11.3.5.2. Market Revenue and Forecast, by Cancer Type

11.3.5.3. Market Revenue and Forecast, by Distribution Channel

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Therapy

11.3.6.2. Market Revenue and Forecast, by Cancer Type

11.3.6.3. Market Revenue and Forecast, by Distribution Channel

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Therapy

11.3.7.2. Market Revenue and Forecast, by Cancer Type

11.3.7.3. Market Revenue and Forecast, by Distribution Channel

11.4. MEA

11.4.1. Market Revenue and Forecast, by Therapy

11.4.2. Market Revenue and Forecast, by Cancer Type

11.4.3. Market Revenue and Forecast, by Distribution Channel

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Therapy

11.4.4.2. Market Revenue and Forecast, by Cancer Type

11.4.4.3. Market Revenue and Forecast, by Distribution Channel

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Therapy

11.4.5.2. Market Revenue and Forecast, by Cancer Type

11.4.5.3. Market Revenue and Forecast, by Distribution Channel

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Therapy

11.4.6.2. Market Revenue and Forecast, by Cancer Type

11.4.6.3. Market Revenue and Forecast, by Distribution Channel

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Therapy

11.4.7.2. Market Revenue and Forecast, by Cancer Type

11.4.7.3. Market Revenue and Forecast, by Distribution Channel

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Therapy

11.5.2. Market Revenue and Forecast, by Cancer Type

11.5.3. Market Revenue and Forecast, by Distribution Channel

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Therapy

11.5.4.2. Market Revenue and Forecast, by Cancer Type

11.5.4.3. Market Revenue and Forecast, by Distribution Channel

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Therapy

11.5.5.2. Market Revenue and Forecast, by Cancer Type

11.5.5.3. Market Revenue and Forecast, by Distribution Channel

Chapter 12. Company Profiles

12.1. Pfizer (USA)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis (Switzerland)

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Roche (Switzerland)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. AstraZeneca (UK)

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Eli Lilly and Company (U.S.)

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Merck & Co., Inc. (U.S.)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Bristol-Myers Squibb (U.S.)

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Sanofi (France)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Johnson & Johnson (U.S.)

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. AbbVie Inc. (U.S.)

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global breast cancer therapeutics market size is expected to increase USD 62.86 billion by 2034 from USD 31.16 billion in 2024.

The global breast cancer therapeutics market will register growth rate of 7.27% between 2025 and 2034.

The major players operating in the breast cancer therapeutics market are Pfizer, Novartis, Roche, AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb, Sanofi, Johnson & Johnson, AbbVie Inc., Gilead Sciences, Celgene Corporation, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company, Limited, Otsuka Pharmaceutical Co., Ltd., Ipsen, and Others.

The driving factors of the breast cancer therapeutics market are the disparities in cancer care and treatment and expansion of novel therapeutic pipelines.

North America region will lead the global breast cancer therapeutics market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client